摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S,2E,4E)-ethyl 6-(tert-butoxycarbonyl)deca-2,4-dienoate | 951035-60-2

中文名称
——
中文别名
——
英文名称
(S,2E,4E)-ethyl 6-(tert-butoxycarbonyl)deca-2,4-dienoate
英文别名
——
(S,2E,4E)-ethyl 6-(tert-butoxycarbonyl)deca-2,4-dienoate化学式
CAS
951035-60-2
化学式
C17H29NO4
mdl
——
分子量
311.422
InChiKey
XPXBMGXRVXWJFP-INVQJTDUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.75
  • 重原子数:
    22.0
  • 可旋转键数:
    8.0
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.65
  • 拓扑面积:
    64.63
  • 氢给体数:
    1.0
  • 氢受体数:
    4.0

反应信息

  • 作为反应物:
    描述:
    (S,2E,4E)-ethyl 6-(tert-butoxycarbonyl)deca-2,4-dienoate 在 palladium on activated charcoal 盐酸sodium hydroxide氢气1-羟基苯并三唑1-(3-二甲基氨基丙基)-3-乙基碳二亚胺三乙胺 作用下, 以 四氢呋喃1,4-二氧六环乙醇二氯甲烷 为溶剂, 反应 12.0h, 生成 (S)-6-(2-hydroxypentadecanamido)decanoic acid
    参考文献:
    名称:
    Structure−Activity Relationship of 2-Oxoamide Inhibition of Group IVA Cytosolic Phospholipase A2 and Group V Secreted Phospholipase A2
    摘要:
    The Group IVA cytosolic phospholipase A(2) (GIVA cPLA(2)) is a key provider of substrates for the production of eicosanoids and platelet-activating factor. We explored the structure-activity relationship of 2-oxoamide-based compounds and GIVA cPLA(2) inhibition. The most potent inhibitors are derived from delta- and gamma-amino acid-based 2-oxoamides. The optimal side-chain moiety is a short nonpolar aliphatic chain. All of the newly developed 2-oxoamides as well as those previously described have now been tested with the human Group V secreted PLA(2) (GV sPLA(2)) and the human Group VIA calcium-independent PLA(2) (GVIA iPLA(2)). Only one 2-oxoamide compound had appreciable inhibition of GV sPLA(2), and none of the potent GIVA cPLA(2) inhibitors inhibited either GV sPLA(2) or GVIA iPLA(2). Two of these specific GIVA cPLA(2) inhibitors were also found to have potent therapeutic effects in animal models of pain and inflammation at dosages well below the control nonsteroidal anti-inflammatory drugs.
    DOI:
    10.1021/jm0613673
  • 作为产物:
    描述:
    tert-butyl (S)-(1-hydroxyhexan-2-yl)carbamate 在 2,2,6,6-tetramethylpiperidine-1-yloxy free radical lithium hydroxide 、 sodium hypochlorite 、 molecular sieve 、 碳酸氢钠 、 sodium bromide 作用下, 以 四氢呋喃乙酸乙酯甲苯 为溶剂, 反应 12.0h, 生成 (S,2E,4E)-ethyl 6-(tert-butoxycarbonyl)deca-2,4-dienoate
    参考文献:
    名称:
    Structure−Activity Relationship of 2-Oxoamide Inhibition of Group IVA Cytosolic Phospholipase A2 and Group V Secreted Phospholipase A2
    摘要:
    The Group IVA cytosolic phospholipase A(2) (GIVA cPLA(2)) is a key provider of substrates for the production of eicosanoids and platelet-activating factor. We explored the structure-activity relationship of 2-oxoamide-based compounds and GIVA cPLA(2) inhibition. The most potent inhibitors are derived from delta- and gamma-amino acid-based 2-oxoamides. The optimal side-chain moiety is a short nonpolar aliphatic chain. All of the newly developed 2-oxoamides as well as those previously described have now been tested with the human Group V secreted PLA(2) (GV sPLA(2)) and the human Group VIA calcium-independent PLA(2) (GVIA iPLA(2)). Only one 2-oxoamide compound had appreciable inhibition of GV sPLA(2), and none of the potent GIVA cPLA(2) inhibitors inhibited either GV sPLA(2) or GVIA iPLA(2). Two of these specific GIVA cPLA(2) inhibitors were also found to have potent therapeutic effects in animal models of pain and inflammation at dosages well below the control nonsteroidal anti-inflammatory drugs.
    DOI:
    10.1021/jm0613673
点击查看最新优质反应信息